Company: INGN
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029993
Chunk: 150

Company: Inogen Inc
Filing Date: 2025-02-28
Form: 10-K
Item: Item 7
Chunk 150
---
DA and Adjusted EBITDA for business planning purposes, to incentivize and compensate our management personnel, and in evaluating acquisition opportunities. In addition, we believe EBITDA and Adjusted EBITDA and similar measures are widely used by investors, securities analysts, ratings agencies, and other parties in evaluating companies in our industry as a measure of financial performance and debt-service capabilities.

 72

Our uses of EBITDA and Adjusted EBITDA have limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of our results as reported under U.S. GAAP. Some of these limitations are: 

•EBITDA and Adjusted EBITDA do not reflect our cash expenditures for capital equipment or other contractual commitments; 

•although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and EBITDA and Adjusted EBITDA do not reflect capital expenditure requirements for such replacements; 

•EBITDA and Adjusted EBITDA do not reflect changes in, or cash requirements for, our working capital needs; 

•Adjusted EBITDA does not include changes in fair value of earnout liability related to our acquisitions; 

•Adjusted EBITDA does not include acquisition-related expenses, whether the acquisition was consummated or not pursued; 

•Adjusted EBITDA does not include costs associated with workforce reductions and associated costs and other restructuring-related activities;

•goodwill impairment; and

•other companies, including companies in our industry, may calculate EBITDA and Adjusted EBITDA measures differently, which reduces their usefulness as a comparative measure. 

In evaluating EBITDA and Adjusted EBITDA, we anticipate that in the future we will incur expenses within these categories similar to this presentation. Our presentation of EBITDA and Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by certain expenses. When evaluating our financial results, EBITDA and Adjusted EBITDA should be considered alongside other financial performance measures, including U.S. GAAP results.

The following table presents a reconciliation of EBITDA and Adjusted EBITDA to our net loss, the most comparable U.S. GAAP measure, for each of the periods indicated:

    (amounts in thousands)
     
    Years ended December 31,

    Non-GAAP EBITDA and Adjusted EBITDA
     
    2024

    2023